Vivos Therapeutics (VVOS) Liabilities and Shareholders Equity (2019 - 2026)

Vivos Therapeutics (VVOS) has reported Liabilities and Shareholders Equity for 8 consecutive years, with $25.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 121.97% year-over-year to $25.0 million; the TTM figure through Mar 2026 stood at $101.9 million (up 76.39% YoY), while the FY2025 annual figure was $25.2 million, up 64.56% from the prior year.
• Liabilities and Shareholders Equity held at $25.0 million in Q1 2026 per VVOS's latest filing, from $25.2 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $29.6 million in Q1 2022 and bottomed at $10.3 million in Q3 2023.
• Historically, Liabilities and Shareholders Equity has averaged $18.2 million across 5 years, with a median of $15.8 million in 2024.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity sank 59.27% — and 2026, when it surged 121.97%.
• Vivos Therapeutics' Liabilities and Shareholders Equity stood at $13.7 million in 2022, then fell by 21.79% to $10.7 million in 2023, then surged by 42.44% to $15.3 million in 2024, then soared by 64.56% to $25.2 million in 2025, then fell by 0.43% to $25.0 million in 2026.
• Business Quant data shows VVOS's Liabilities and Shareholders Equity at $25.0 million in Q1 2026, $25.2 million in Q4 2025, and $25.6 million in Q3 2025.